Advertisement
Advertisement
U.S. Markets open in 6 hrs 37 mins
Advertisement
Advertisement
Advertisement
Advertisement

Century Therapeutics, Inc. (IPSC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.31+1.24 (+6.18%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.07
Open19.65
Bid0.00 x 800
Ask0.00 x 3200
Day's Range19.33 - 21.44
52 Week Range16.29 - 32.90
Volume53,338
Avg. Volume195,023
Market Cap1.168B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.25
  • GlobeNewswire

    Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

    Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, and Outpace Bio, a cutting-edge biotechnology company buil

  • GlobeNewswire

    Century Therapeutics Announces Its Addition to the Russell 2000® Index

    PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. “Century’s inclusion in the Russe

  • GlobeNewswire

    Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

    Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent IPO with net proceeds of approximately $221MJune 30, 2021 cash, cash equivalents, and marketable securities of $440M PHILADELPHIA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reporte

Advertisement
Advertisement